Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05493514
Recruiting Observational

Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System

NCT05493514 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Don Carlo Gnocchi ETS
Phase
Observational
Started
2022-05-13
Last updated
2022-08-09

Condition(s) studied

Multiple SclerosisStrokeParkinson DiseaseAcquired Brain Injury

Investigational drug(s) / intervention(s)

Robotic Assisted Gait Training with G-EO system

Robotic Assisted Gait Training with G-EO system: Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.

Study summary

The aim of this work is to elaborate a statistical model to predict the effectiveness of robotic treatment in subjects with neurological diseases. The model will be used to understand which subjects are most responsive to this type of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Multiple Sclerosis, Parkinson Disease, Stroke or acquired brain injury * Minimum number of sessions: 10 sessions with the GEO system * Minimum frequency of sessions: 2 per week * Age ≥ 18 years * Ability to walk for at least 10 meters, also with aid * Indication of robotic treatment in the therapeutic plan * Body size suitable for the robotic device * ability to maintain verticality for 7 minutes; * ability to maintain the sitting position without support for 30 seconds; Exclusion Criteria: * severe limitations of articular range of motion; * medical problems compromising walking (e.g. fractures, pain, severe osteoporosis or severe spasticity); * Presence of skin lesions in the areas of contact with the device; * Presence of seizures that may be triggered by the use of the G-EO system.

Primary outcome measure(s)

  • Change in gait speed — baseline (T0), at the end of the treatment in accordance with the duration foreseen by the therapeutic plan of each subject up to a minimum of 2 weeks, (T1) and 2 months of follow up
    The 10 Meter Walk Test is a performance measure used to assess walking speed in meters per second over a short distance. The time to cover 6 meters is measured and the walking speed is calculated. higher speed indicates better performance.

Trial sites (1)

FacilityCityRegionStatus
Don Gnocchi Foundation Milan Italy Recruiting

More Fondazione Don Carlo Gnocchi ETS trials in Italy

Saliva and Extracellular Vesicles for Neurodegenerative Diseases Recruiting
Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia Recruiting
Validation of a Digital Intervention to Rehabilitate Cognitive Resources Recruiting
Shared Interactive Book Reading in Preschool Children With Neurodevelopmental Disorders: Effects on Language Development and Reading Habits Active, not recruiting
Clinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. Starting soon

Other trials for the same condition

Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna Recruiting
Saliva and Extracellular Vesicles for Neurodegenerative Diseases Recruiting
Effects of Trans-Auricular Vagal Stimulation on Neuromotor Recovery in Subacute Stroke During Technological and Traditional Training Recruiting
Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study Starting soon
Effectiveness of Cognitive Stimulation Treatment in Patients With Parkinson's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05493514 on ClinicalTrials.gov ↗ ← All trials in Italy